Drugs / Trimethoprim/Sulfamethoxazole
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06499233 | Jul 2024 → Jul 2026 overdue | autoimmune disease, pneumocystosis, rheumatic disorder | Tongji Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trimethoprim/Sulfamethoxazole | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06499233 ↗ |
| Known as | TMP/SMX | “Patients received Trimethoprim/Sulfamethoxazole (TMP/SMX) 480 mg p.o. every day as PJP Prophylaxis” NCT06499233 ↗ |
| Route | Oral | “480 mg p.o. every day” NCT06499233 ↗ |